<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03921138</url>
  </required_header>
  <id_info>
    <org_study_id>SLH</org_study_id>
    <nct_id>NCT03921138</nct_id>
  </id_info>
  <brief_title>Opportunistic Salpingectomy at the Time of Benign Laparoscopic Hysterectomy</brief_title>
  <acronym>SLH</acronym>
  <official_title>Opportunistic Salpingectomy at the Time of Benign Laparoscopic Hysterectomy : Assessment of Possible Complications and Histopathological Tumor Protein 53 (p53)-Signatures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective study, patients who underwent benign laparoscopic hysterectomy with
      systematic salpingectomy were included. The aim of this study is to assess the prevalence of
      tubal histopathological abnormalities such as Serous Tubal Intraepithelial Carcinoma (STIC)
      and tumor protein 53 (p53) signatures) as well as the prevalence of perioperative and
      postoperative complications related to opportunistic laparoscopic salpingectomy in a low risk
      population. The hypothesis is that prophylactic salpingectomy during benign laparoscopic
      hysterectomy is both feasible and innocuous. Peri- and postoperative complications, duration
      of salpingectomy and post-salpingectomy blood loss, histopathological and immunohistochemical
      analysis with anti-p53 antibody were evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2014</start_date>
  <completion_date type="Actual">January 31, 2016</completion_date>
  <primary_completion_date type="Actual">January 31, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Histopathologic tube anomalies</measure>
    <time_frame>day 1 of surgery</time_frame>
    <description>Prevalence of histopathologic tube anomalies (Serous Tubal Intraepithelial Carcinoma STIC or tumor protein 53 (p53) lesion)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Benign Laparoscopic Hysterectomy</condition>
  <condition>Systematic Salpingectomy</condition>
  <arm_group>
    <arm_group_label>Benign laparoscopic hysterectomy</arm_group_label>
    <description>Patients who underwent benign laparoscopic hysterectomy with systematic salpingectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Histopathologic tube anomalies</intervention_name>
    <description>Assessment of prevalence of histopathologic tube anomalies (Serous Tubal Intraepithelial Carcinoma (STIC) or tumor protein 53 (p53) lesion)</description>
    <arm_group_label>Benign laparoscopic hysterectomy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Female patients who underwent benign laparoscopic hysterectomy with systematic
        salpingectomy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who underwent benign laparoscopic hysterectomy with systematic salpingectomy

        Exclusion Criteria:

          -  Hysterectomy in a context of gynecologic cancer

          -  Hysterectomy not carried out using laparoscopy

          -  Fimbriated end missing or damaged or impossible for pathologist to analyze
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gautier Chene, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon (Hôpital Femme Mère Enfant)</affiliation>
  </overall_official>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2019</study_first_posted>
  <last_update_submitted>April 16, 2019</last_update_submitted>
  <last_update_submitted_qc>April 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

